Shin Nippon Biomedical Laboratories (TSE:2395) Stock May Rerate On 4x EPS Growth

Shin Nippon Biomedical Laboratories stock has quietly climbed in recent weeks, yet the real story sits in the earnings line. Q1 FY2027 basic earnings per share of ¥25.56 and net income of ¥1,064.04m landed on top of a trailing twelve month P/E of roughly 11.3x, which is well below both peers and the broader Japanese market. That combination of solid profitability and discounted valuation is the headline. The short term question is how traders treat the latest quarter. The longer term question is whether this earnings profile justifies a rerating.

If you like Shin Nippon Biomedical Laboratories’ earnings profile but want a broader range of stocks with similar quality on more attractive terms, or a stronger balance between price and profitability, check out the 17 high quality undervalued stocks.

Q1 2027 Earnings Summary

• Revenue (Q1 2027 vs. Q1 2026): ¥7,868.873m vs. ¥6,477.677m (up about 21.5%)
• Net Income (Excl. Extra Items, Q1 2027 vs. Q1 2026): ¥1,064.042m vs. ¥260.425m (up more than 4x)
• Basic EPS (Q1 2027 vs. Q1 2026): ¥25.56 vs. ¥6.26 (up more than 4x)
• Net Profit Margin (Trailing 12 Months vs. Prior Year): 15.8% vs. 15.2% (modest improvement in profitability)

Prefer clean visual charts instead of another wall of earnings tables and ratios? See Shin Nippon Biomedical Laboratories’ full financial picture, with a clear view of its valuation and earnings profile, in our company report for Shin Nippon Biomedical Laboratories.

Stronger Earnings Support Shin Nippon Biomedical Bull Story

For anyone leaning bullish on Shin Nippon Biomedical Laboratories, the latest quarter gives the CRO and IP driven narrative some backing. Revenue of ¥7,868.873m versus ¥6,477.677m and basic EPS of ¥25.56 versus ¥6.26 point to a business that is scaling its core services while converting more of that activity into profit. Net profit margin also sits slightly higher at 15.8% versus 15.2%. That combination fits a view that the underlying research services and related licensing activities are holding up well as a cash generating core.

Conglomerate Complexity Risks Not Fully Put To Bed

The broader diversification story around Shin Nippon Biomedical Laboratories still cuts both ways. Earnings are currently strong, yet the company remains exposed to very different businesses such as hospitality and geothermal power alongside CRO work. That mix can make future cash flows harder to interpret and may feed concerns about a conglomerate style discount. At the same time, margin stability around 15% and very large year on year net income growth indicate that immediate financial strain is not the central concern in the current numbers. The key risk remains clarity of focus rather than current performance pressure.

Compare Shin Nippon Biomedical Laboratories’ stronger margins and earnings with how the market values the stock after the recent move to ¥1,456. Track whether analysts think this earnings profile supports more upside or is already priced in with the consensus price target analysis for Shin Nippon Biomedical Laboratories.

Stay Ahead With Simply Wall St

If Shin Nippon Biomedical Laboratories’ low P/E and recent jump in earnings have caught your eye, register for free with Simply Wall St and add it to a Watchlist to watch how the share price moves against its fair value and wait for a setup that fits your plan. After you own the stock, use the Portfolio Command Center to cut through noise and focus on the key fundamental and price updates that matter for your holdings. For a wider view, tap into crowd insights with the Community and see how other investors are thinking about the same risks and opportunities. By spotting hidden catalysts and potential red flags early, you can stay informed about the market and make decisions with more confidence.

Seeking Alternatives Beyond Shin Nippon Biomedical

Fresh ideas tend to move first when momentum builds and many investors only notice once prices are already rising sharply. Look under the radar while attention is still limited, before the broader crowd catches up, to position earlier in the move.

• Look for underappreciated quality as it starts to gain traction by running your next screen through a curated set of 63 high quality undiscovered gems that most investors have not focused on yet.
• Explore potential breakout trends in sectors where sentiment is still evolving by focusing on a hand picked 56 resilient stocks with low risk scores that aims to keep downside in check.
• Track momentum in companies tied to physical assets while other investors remain hesitant by filtering opportunities through a focused group of 32 elite gold producer stocks before attention broadens.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com